Researchers Submit Patent Application, "Rna Editor-Enhanced Rna Trans-Splicing", for Approval (USPTO 20230121437).

A composition comprising: (i) a first recombinant adeno-associated virus (rAAV) particle comprising the isolated nucleic acid of any one of claims 1 to 14; and (ii) a second rAAV particle encoding an RNA-guided nuclease, optionally, wherein the RNA-guided nuclease is a Cas13 nuclease. The method of any one of claims 39-44, wherein the RNA-guided nuclease is a Cas13 nuclease, optionally wherein the Cas13 nuclease is Cas13b, Cas13d, or dCas13d. The isolated nucleic acid of any one of claims 1 to 14, wherein the expression construct further comprises: (v) a sequence encoding an RNA-guided nuclease; optionally, wherein the RNA-guided nuclease is a Cas13 nuclease. The composition of claim 21, wherein the composition further comprises an isolated nucleic acid encoding an RNA-guided nuclease, optionally wherein the RNA-guided nuclease is a Cas13 nuclease. [Extracted from the article]